Page History
...
SUPPLEMENTAL LIST ICD-10-CM (EFFECTIVE DATES: 10/1/20202021-09/30/2021)/30/2022)
ICD-10-CM Code | Explanation of Code | ||
---|---|---|---|
ICD-10-CM Code | Explanation of Code | ||
C00.- - C43.-, C4A.-,C45.- - C48.-, C49.- -C96.- | Malignant neoplasms (excluding category C44 and C49.A), stated or presumed to be primary (of specified site) and certain specified histologies | ||
C44.00, C44.09 | Unspecified/other malignant neoplasm of skin of lip | ||
C44.10-, C44.19- | Unspecified/other malignant neoplasm of skin of eyelid | ||
C44.13- | Sebaceous cell carcinoma of skin of eyelid, including canthus Note: Effective 10/1/2018 | ||
C44.20-, C44.29- | Unspecified/other malignant neoplasm skin of ear and external auricular canal | ||
C44.30-, C44.39- | Unspecified/other malignant neoplasm of skin of other/unspecified parts of face | ||
C44.40, C44.49 | Unspecified/other malignant neoplasm of skin of scalp & neck | ||
C44.50-, C44.59- | Unspecified/other malignant neoplasm of skin of trunk | ||
C44.60-, C44.69- | Unspecified/other malignant neoplasm of skin of upper limb, incl. shoulder | ||
C44.70-, C44.79- | Unspecified/other malignant neoplasm of skin of lower limb, including hip | ||
C44.80, C44.89 | Unspecified/other malignant neoplasm of skin of overlapping sites of skin | ||
C44.90, C44.99 | Unspecified/other malignant neoplasm of skin of unspecified sites of skin | ||
C49.A- | Gastrointestinal Stromal Tumors Note: GIST is only reportable when it is malignant (/3). GIST, NOS (not stated whether malignant or benign) is a /1 and is not reportable. | ||
D00.- - D09.- | In-situ neoplasms Note: Carcinoma in situ of the cervix (CIN III-8077/2) and Prostatic Intraepithelial Carcinoma (PIN III-8148/2) are not reportable | ||
D18.02 | Hemangioma of intracranial structures and any site | ||
D32.- | Benign neoplasm of meninges (cerebral, spinal and unspecified) | ||
D33.- | Benign neoplasm of brain and other parts of central nervous system | ||
D35.2 - D35.4 | Benign neoplasm of pituitary gland, craniopharyngeal duct and pineal gland | ||
D42.-, D43.- | Neoplasm of uncertain or unknown behavior of meninges, brain, CNS | ||
D44.3 - D44.5 | Neoplasm of uncertain or unknown behavior of pituitary gland, craniopharyngeal duct and pineal gland | ||
D45 | Polycythemia vera (9950/3) ICD-10-CM Coding instruction note: Excludes familial polycythemia (C75.0), secondary polycythemia (D75.1) | ||
D46.- | Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992) | ||
D47.02 | Systemic mastocytosis | ||
D47.1 | Chronic myeloproliferative disease (9963/3, 9975/3) ICD-10-CM Coding instruction note: Excludes the following: Atypical chronic myeloid leukemia BCR/ABL-negative (C92.2_) Chronic myeloid leukemia BCR/ABL-positive (C92.1_) Myelofibrosis & Secondary myelofibrosis (D75.81) Myelophthisic anemia & Myelophthisis (D61.82) | ||
D47.3 | Essential (hemorrhagic) thrombocythemia (9962/3) Includes: Essential thrombocytosis, idiopathic hemorrhagic thrombocythemia | ||
D47.4 | Osteomyelofibrosis (9961/3) Includes: Chronic idiopathic myelofibrosis Myelofibrosis (idiopathic) (with myeloid metaplasia) Myelosclerosis (megakaryocytic) with myeloid metaplasia) Secondary myelofibrosis in myeloproliferative disease | ||
D47.9 | Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9970/1, 9931/3) | ||
D47.Z- | Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9960/3, 9970/1, 9971/3, 9931/3) | ||
D49.6, D49.7 | Neoplasm of unspecified behavior of brain, endocrine glands and other CNS | ||
D72.110 | Idiopathic hypereosinophilic syndrome [HES] | ||
D72.111 | Lymphocytic Variant Hypereosinophilic Syndrome [LHES] | ||
D72.118 | Other hypereosinophilic syndrome | ||
D72.119 | Hypereosinophilic syndrome [HES], unspecified | ||
R85.614 | Cytologic evidence of malignancy on smear of anus | ||
R87.614 | Cytologic evidence of malignancy on smear of cervix | ||
R87.624 | Cytologic evidence of malignancy on smear of vagina|||
B20 | Human immunodeficiency virus [HIV] disease with other diseases | ||
B97.33, B97.34, B97.35 | Human T-cell lymphotrophic virus, (type I [HTLV-1], type II [HTLV-II], type 2 [HIV 2]) as the cause of diseases classified elsewhere | ||
B97.7 | Papillomavirus as the cause of diseases classified elsewhere | ||
C44.01, C44.02 | Basal/squamous cell carcinoma of skin of lip | ||
C44.11-, C44.12- | Basal/squamous cell carcinoma of skin of eyelid | ||
C44.21-, C44.22- | Basal/squamous cell carcinoma of skin of ear and external auricular canal | ||
C44.31-, C44.32- | Basal/squamous cell carcinoma of skin of other and unspecified parts of face | ||
C44.41, C44.42 | Basal/squamous cell carcinoma of skin of scalp and neck | ||
C44.51-, C44.52- | Basal/squamous cell carcinoma of skin of trunk | ||
C44.61-, C44.62- | Basal/squamous cell carcinoma of skin of upper limb, including shoulder | ||
C44.71-, C44.72- | Basal/squamous cell carcinoma of skin of lower limb, including hip | ||
C44.81, C44.82 | Basal/squamous cell carcinoma of skin of overlapping sites of skin | ||
C44.91, C44.92 | Basal/squamous cell carcinoma of skin of unspecified sites of skin | ||
D06.- | Carcinoma in situ of the cervix | ||
D10.- - D31.-, D34, D35.0, D35.1, D35.5-,D35.9, D36.- | Benign neoplasms (see "must collect" list for reportable benign neoplasms) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors Note: Borderline cystadenomas M-8442, 8451, 8462, 8472, 8473, of the ovaries moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. SEER registries are not required to collect these cases for diagnoses made 1/1/2001 and after. However, cases diagnosed prior to 1/1/2001 should still be abstracted and reported to SEER. | ||
D37. _ - D41. _ | Neoplasms of uncertain or unknown behavior (see "must collect" list for reportable neoplasms of uncertain or unknown behavior) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors | D3A._ | Benign carcinoid tumors |
D44.0 - D44.2, D44.6-D44.9 | Neoplasm of uncertain or unknown behavior of other endocrine glands (see "must collect" list for D44.3-D44.5) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors | ||
D47.01 | Cutaneous mastocytosis (9740/1) | ||
D47.09 | Other mast cell neoplasms of uncertain behavior | ||
D47.2 | Monoclonal gammopathy Note: Screen for incorrectly coded Waldenstrom’s macroglobulinemia | ||
D47.Z2 | Castleman disease | ||
D48.- | Neoplasm of uncertain behavior of other and unspecified sites | ||
D49.0 - D49.9 | Neoplasm of unspecified behavior (except for D49.6 and D49.7) | ||
D61.1 | Drug-induced aplastic anemia (also known as “aplastic anemia due to antineoplastic chemotherapy”) ICD-10-CM Coding instruction note: Use additional code for adverse effect, if applicable, to identify drug | ||
D61.810 | Antineoplastic chemotherapy induced pancytopenia | ||
D61.82 | Myelophthisis ICD-10-CM Coding instruction: Code first the underlying disorder, such as: malignant neoplasm of breast (C50. _) | ||
D63.0 | Anemia in neoplastic disease ICD-10-CM Coding instruction: Code first neoplasm (C00-C49) | ||
D64.81 | Anemia due to antineoplastic chemotherapy | ||
D69.49, D69.59, D69.6 | Other thrombocytopenia Note: Screen for incorrectly coded thrombocythemia | ||
D70.1 | Agranulocytosis secondary to cancer chemotherapy ICD-10-CM Coding instruction: code also underlying neoplasm | ||
D75.81 | Myelofibrosis (note: this is not primary myelofibrosis [9961/3] ICD-10-CM Coding instruction note: Code first the underlying disorder, such as: malignant neoplasm of breast (C50. _) | ||
D76.- | Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue | ||
D89.0, D89.1 | Other disorders involving the immune mechanism, not elsewhere classified Note: Review for miscodes | ||
D89.4- | Mast cell activation syndrome and related disorders | ||
E08 | Diabetes mellitus due to underlying condition ICD-10-CM Coding instruction note: Code first the underlying condition, such as: malignant neoplasm (C00-C96) | ||
E31.2- | Multiple endocrine neoplasia [MEN] syndromes ICD-10-CM Coding instruction: Code also any associated malignancies and other conditions associated with the syndromes | ||
E34.0 | Carcinoid syndrome ICD-10-CM Coding instruction: May be used as an additional code to identify functional activity associated with a carcinoid tumor | ||
E83.52 | Hypercalcemia | ||
E88.09 | Other disorders of plasma-protein metabolism, not elsewhere classified | ||
E88.3 | Tumor lysis syndrome (following antineoplastic chemotherapy) | ||
G13.0 | Paraneoplastic neuromyopathy and neuropathy ICD-10-CM Coding instruction note: Code first underlying neoplasm (C00-D49) | ||
G13.1 | Other systemic atrophy primarily affecting central nervous system in neoplastic disease ICD-10-CM Coding instruction note: Code first underlying neoplasm (C00-D49) | ||
G32.8- | Other specified degenerative disorders of nervous system in diseases classified elsewhere ICD-10-CM Coding instruction note: Code first underlying disease, such as: cerebral degeneration (due to) neoplasm (C00-D49) | ||
G53 | Cranial nerve disorders in diseases classified elsewhere Note: Code first underlying neoplasm (C00-D49) | ||
G55 | Nerve root and plexus compressions in diseases classified elsewhere ICD-10-CM Coding instruction note: code also underlying disease, such as neoplasm (C00-D49) | ||
G63 | Polyneuropathy in diseases classified elsewhere ICD-10-CM Coding instruction note: Code first underlying disease, such as: neoplasm (C00-D49) | ||
G73.1 | Lambert-Eaton syndrome in neoplastic disease ICD-10-CM Coding instruction: Code first underlying neoplasm (C00-D49) | ||
G89.3 | Neoplasm related pain (acute)(chronic) | ||
G99.2 | Myelopathy in diseases classified elsewhere ICD-10-CM Coding instruction: Code first underlying disease, such as: neoplasm (C00-D49) | ||
H47.42 | Disorders of optic chiasm in (due to) neoplasm ICD-10-CM Coding instruction: Code also underlying condition | ||
H47.52- | Disorders of visual pathways in (due to) neoplasm ICD-10-CM Coding instruction: Code also underlying condition | ||
H47.63- | Disorders of visual cortex in (due to) neoplasm ICD-10-CM Coding instruction: Code also underlying condition | ||
J34.81 | Nasal mucositis (ulcerative) | ||
J91.0 | Malignant pleural effusion ICD-10-CM Coding instruction: Code first underlying neoplasm | ||
J93.12 | Secondary spontaneous pneumothorax ICD-10-CM Coding instruction: Code first underlying condition, such as: Malignant neoplasm of bronchus and lung (C34._) Secondary malignant neoplasm of lung (C78.0_) | ||
K12.31 | Oral mucositis (ulcerative) due to antineoplastic therapy | ||
K12.33 | Oral mucositis (ulcerative) due to radiation | ||
K22.711 | Barrett's esophagus with high grade dysplasia | ||
K62.7 | Radiation proctitis | ||
K62.82 | Dysplasia of anus (AIN I and AIN II) | ||
K92.81 | Gastrointestinal mucositis (ulcerated) (due to antineoplastic therapy) | ||
L10.81 | Paraneoplastic pemphigus | ||
M31.11 | Hematopoietic stem cell transplantation-associated thrombotic microangioplasty Note: Effective 10/1/2021 | ||
M36.0 | Dermato(poly)myositis in neoplastic disease ICD-10-CM Coding instruction: Code first underlying neoplasm (C00-D49) | ||
M36.1 | Arthropathy in neoplastic disease ICD-10-CM Coding instruction: Code first underlying neoplasm, such as: Leukemia (C91-C95), malignant histiocytosis (C96.A), multiple myeloma (C90.0) | ||
M84.5- | Pathologic fracture in neoplastic disease ICD-10-CM Coding instruction: Code also underlying neoplasm (C00-D49) | ||
M90.6- | Osteitis deformans in neoplastic disease ICD-10-CM Coding instruction: Code first the neoplasm (C40._, C41._) | ||
N42. 3Dysplasia of prostate (PIN I and PIN II)3 | Dysplasia of prostate (PIN I and PIN II) | ||
N52.35 | Erectile dysfunction following radiation therapy | ||
N52.36 | Erectile dysfunction following interstitial seed therapy | ||
N76.81 | Mucositis (ulcerative) of vagina and vulva | ||
N87.- | Dysplasia of cervix uteri (CIN I and CIN II) | ||
N89.0, N89.1, N89.3 | Vaginal dysplasia (VIN I and VIN II) | ||
N90.0, N90.1, N90.3 | Vulvar dysplasia (VAIN I and VAIN II) | ||
O01.- | Hydatidiform mole Note: Benign tumor that can become malignant. If malignant, report as Choriocarcinoma (9100/3, ) malignancy code in the C00- C97 range | ||
O9A.1- | Malignant neoplasm complicating pregnancy, childbirth and the puerperium (conditions in C00-C96) ICD-10-CM Coding instruction: Use additional code to identify neoplasm | ||
P04.11 | Newborn affected by maternal antineoplastic chemotherapy Note: Effective 10/1/2018 | ||
P04.12 | Newborn affected by maternal cytotoxic drugs | ||
Q85.0- | Neurofibromatosis (nonmalignant) (9540/1) Note: Neurofibromatosis is not cancer. These tumors can be precursors to acoustic neuromas, which are reportable | ||
R18.0 | Malignant ascites ICD-10-CM Coding instruction: Code first malignancy, such as: Malignant neoplasm of ovary (C56. _), secondary malignant neoplasm of retroperitoneum and peritoneum (C78.6) | ||
R53.0 | Neoplastic (malignant) related fatigue ICD-10-CM Coding instruction: Code first associated neoplasm | ||
R59.- | Enlarged lymph nodes | ||
R85.6- | Abnormal findings on cytological and histological examination of digestive organs Note: see "must collect" list for R85.614 | ||
R87.61-, R87.62- | Abnormal findings on cytological/histological examination of female genital organs Note: see "must collect" list for R87.614 and R87.624 | ||
R92.- | Abnormal findings on diagnostic imaging of breast | ||
R97.- | Abnormal tumor markers | ||
T38.6- | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified | ||
T38.8-, T38.9- | Poisoning by hormones and their synthetic substitutes | ||
T45.1- | Poisoning by, adverse effect of and under dosing of antineoplastic and immunosuppressive drugs | ||
T45.8-, T45.9- | Poisoning by primary systemic and hematological agent, unspecified | ||
T66 | Unspecified effects of radiation | ||
T80.1 | Vascular complications following infusion, transfusion and therapeutic injection | ||
T80.2- | Infections following infusion, transfusion and therapeutic injection | ||
T80.810 | Extravasation of vesicant antineoplastic chemotherapy | ||
T80 .818.818 | Extravasation of other vesicant agent | ||
T80.82 | Complication of immune effector cellular therapy Complication of chimeric antigen receptor (CAR-T) cell therapy Extravasation of other vesicant agent | ||
T86.0 | Complications of bone marrow transplant ICD-10-CM Coding instruction: Use addition code to identify other transplant complications, such as: malignancy associated with organ transplant (C80.2) or post-transplant lymphoproliferative disorders (PTLD) (D47.Z1) | ||
Y63.2 | Overdose of radiation given during therapy | ||
Y84.2 | Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, | or of later complication, without mention of misadventure at the time of the procedure | |
Z03.89 | Encounter for observation for other suspected diseases and conditions ruled out | ||
Z08 | Encounter for follow-up examination after completed treatment for malignant neoplasm (medical surveillance following completed treatment) ICD-10-CM Coding instruction: Use additional code to identify the personal history of malignant neoplasm (Z85._) | ||
Z12.- | Encounter for screening for malignant neoplasms | ||
Z13.0 | Encounter for screening for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | ||
Z15.0 | Genetic susceptibility to malignant neoplasm ICD-10-CM Coding instruction: Code first, if applicable, any current malignant neoplasm (C00-C75, C81-C96); Use additional code, if applicable, for any personal history of malignant neoplasm (Z85._) | ||
Z17.0, Z17.1 | Estrogen receptor positive and negative status ICD-10-CM Coding instruction: Code first malignant neoplasm of breast (C50._) | ||
Z40.0- | Encounter for prophylactic surgery for risk factors related to malignant neoplasms | ||
Z42.1 | Encounter for breast reconstruction following mastectomy | ||
Z48.290 | Encounter for aftercare following bone marrow transplant | ||
Z48.3 | Aftercare following surgery for neoplasm ICD-10-CM Coding instruction: Use additional code to identify the neoplasm | ||
Z51.0 | Encounter for antineoplastic radiation therapy | ||
Z51.1- | Encounter for antineoplastic chemotherapy and immunotherapy | ||
Z51.5, Z51.89 | Encounter for palliative care and other specified aftercare | ||
Z79.81- | Long term (current) use of agents affecting estrogen receptors and estrogen levels ICD-10-CM Coding instruction: Code first, if applicable, malignant neoplasm of breast (C50._), malignant neoplasm of prostate (C61) | ||
Z80.- | Family history of primary malignant neoplasm | ||
Z85.- | Personal history of malignant neoplasm ICD-10-CM Coding instruction: Code first any follow-up examination after treatment of malignant neoplasm (Z08) | ||
Z86.0-, Z86.01-, Z86.03 | Personal history of in situ and benign neoplasms and neoplasms of uncertain behavior | ||
Z92.21, Z92.23, Z92.25, Z92.3 | Personal history of antineoplastic chemotherapy, estrogen therapy, immunosuppression therapy or irradiation (radiation) | ||
Z92.850 | Personal history of Chimeric Antigen Receptor T-cell therapy- Personal history of CAR-T-cell therapy | ||
Z94.81, Z94.84 | Bone marrow and stem cell transplant status |